GILD
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Gilead Sciences, Inc.
- Nom
- Gilead Sciences, Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NASDAQ
- Capitalisation
- $194.9B
- Employés
- 17,000
- PDG
- Daniel O'Day
- Site web
- https://www.gilead.com
- Marché
- ABBVAZNGSKJNJLLYMRK
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 48 000 titres (~7 098 006,30 $ US)
- Insiders
- O''''Day Daniel PatrickWELTERS ANTHONY
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$5,864,148
Avg sell (VWAP, 90d window) $145.54 vs last close $158.69 (+9.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$5,864,148 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $918,427,611/day · 20d vol
- Last synced
-
2026-10-26 21:10:29
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-15 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $156.22 | $468,660 | Form 4 |
| 2026-10-15 | Mercier Johanna | Sell · S · 10b5-1 | 3,000 | $156.22 | $468,660 | Form 4 |
| 2026-10-01 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 3,000 | $148.63 | $445,880 | Form 4 |
| 2026-09-15 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $145.29 | $435,870 | Form 4 |
| 2026-09-15 | Mercier Johanna | Sell · S · 10b5-1 | 600 | $145.29 | $87,174 | Form 4 |
| 2026-09-01 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 5,408 | $149.38 | $807,856 | Form 4 |
| 2026-08-26 | WELTERS ANTHONY | Sell · S · 10b5-1 | 6,880 | $148.82 | $1,023,900 | Form 4 |
| 2026-08-20 | Bluestone Jeffrey | Sell · S · 10b5-1 | 335 | $146.26 | $48,997 | Form 4 |
| 2026-08-17 | Dickinson Andrew D | Sell · S · 10b5-1 | 3,000 | $138.36 | $415,080 | Form 4 |
| 2026-08-17 | Mercier Johanna | Sell · S · 10b5-1 | 11,470 | $138.04 | $1,583,265 | Form 4 |
| 2026-08-03 | O'Day Daniel Patrick | Sell · S · 10b5-1 | 600 | $131.34 | $78,806 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
| 2024-05-10 | Tommy Tuberville | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-07-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-01-27 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-06-06 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-14 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-03-31 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Purchase | $1,001 - $15,000 |
| 2025-03-07 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-12-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-09 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-11-10 | Carol Devine Miller | Sale (Partial) | $15,001 - $50,000 |
| 2021-09-01 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $15,001 - $50,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-01-21 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-09-23 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2020-09-01 | Ed Perlmutter | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-15 | Ed Perlmutter | Purchase | $1,001 - $15,000 |
| 2020-07-08 | Roger Wayne Marshall | Sale (Full) | $1,001 - $15,000 |
| 2020-06-29 | William R. Timmons | Sale (Full) | $1,001 - $15,000 |
| 2020-05-07 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-05 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-04 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-02-07 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-21 | Mikie Sherrill | Purchase | $1,001 - $15,000 |
| 2019-12-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-10-25 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2019-09-19 | Bill Flores | Purchase | $1,001 - $15,000 |
| 2019-05-13 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2019-05-08 | Bill Flores | Sale (Full) | $1,001 - $15,000 |
| 2019-04-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-03-25 | Bill Flores | Purchase | $1,001 - $15,000 |
| 2019-03-19 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2019-01-04 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2018-12-21 | Greg Gianforte | Purchase | $15,001 - $50,000 |
| 2018-11-26 | John Yarmuth | Sale (Full) | $1,001 - $15,000 |
| 2018-07-17 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2017-07-17 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
| 2017-04-17 | Josh Gottheimer | Sale (Full) | $1,001 - $15,000 |
| 2017-04-04 | Gary James Palmer | Purchase | $1,001 - $15,000 |
| 2017-02-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-20 Drivers: Congress, trend, fundamentals. Insiders: neutral. Moteurs : Congrès, tendance, fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $4.9M) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $4.9M) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Supports a bullish reading. 3 purchase disclosures year to date
- Timing Supports a bullish reading. Interesting trend — weekly bias up
- Financial indicators Supports a bullish reading. Current ratio 1.55 · operating margin 40%
Suggested stop 142.39, nearest stored support minus 0.5 ATR(10.3% under the last close). Reward/risk to the next stored resistance is 0.11. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-19 All You Need to Know About Gilead (GILD) Rating Upgrade to Buy Gilead (GILD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-10-19 Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treatment, HIV prevention and new insights into broader experiences of people living with HIV, as well as emerging antiviral programs. “We remain committed to advancing options for people a.
- 2026-10-19 Gilead''s pill succeeds in mid-stage bowel disease trial Gilead''s pill succeeds in mid-stage bowel disease trial
- 2026-10-19 Insider Selling: Gilead Sciences (NASDAQ:GILD) Insider Sells $468,660.00 in Stock Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the firm''s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the insider directly owned 113,684 shares of the company''s
- 2026-10-19 Insider Selling: Gilead Sciences (NASDAQ:GILD) CFO Sells $468,660.00 in Stock Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business''s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company''s stock,
- 2026-10-18 Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There''s No Tomorrow? Gilead Sciences'' financial results have been strong this year. The company could improve even more thanks to recent approvals and label expansions.
- 2026-10-15 Gilead Sciences (GILD) Rises Higher Than Market: Key Facts Gilead Sciences (GILD) closed the most recent trading day at $157.48, moving +2.57% from the previous trading session.
- 2026-10-15 Can Gilead''s Deal With VIR Boost Its Oncology Pipeline and Growth? Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
- 2026-10-15 The Big 3: MRK, GILD, XOM The significant rotation in the AI trade, particularly in neoclouds like CoreWeave (CRVW), is something Dan Deming believes opens the door to new trading opportunities. He sees Merck (MRK) leading a stabilizing healthcare sector, Gilead Sciences (GILD) as a stock "poised to continue upward price action," and Exxon Mobil (XOM) as a high-liquid name in a booming energy trade.
- 2026-10-15 Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock''s prospects.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | |
| Ebit Margin | 36.8% | 5.8% | 28.8% | 24.7% | 34.0% | |
| Ebitda Margin | 46.1% | 15.4% | 38.7% | 32.4% | 41.5% | |
| Operating Profit Margin | 39.7% | 5.8% | 28.0% | 26.9% | 36.3% | |
| Pretax Profit Margin | 33.3% | 2.4% | 25.3% | 21.3% | 30.3% | |
| Continuous Operations Profit Margin | 28.9% | 1.7% | 20.7% | 16.7% | 22.7% | |
| Net Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Bottom Line Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Current Ratio | 1.553 | 1.597 | 1.426 | 1.285 | 1.272 | |
| Quick Ratio | 1.403 | 1.455 | 1.268 | 1.151 | 1.133 | |
| Solvency Ratio | 0.310 | 0.082 | 0.212 | 0.160 | 0.176 | |
| Cash Ratio | 0.640 | 0.832 | 0.539 | 0.482 | 0.460 | |
| Price To Earnings Ratio | 17.944 | 243.079 | 17.844 | 23.456 | 14.639 | |
| Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Forward Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Price To Earnings Diluted Ratio | 18.103 | 243.079 | 18.002 | 23.585 | 14.728 | |
| Price To Earnings Diluted Growth Ratio | 0.011 | -2.655 | 0.762 | -0.901 | 0.003 | |
| Price To Book Ratio | 6.726 | 5.959 | 4.428 | 5.073 | 4.329 | |
| Price To Sales Ratio | 5.186 | 4.006 | 3.728 | 3.949 | 3.340 | |
| Price To Free Cash Flow Ratio | 16.147 | 11.178 | 13.624 | 12.912 | 8.440 | |
| Price To Operating Cash Flow Ratio | 15.240 | 10.638 | 12.628 | 11.876 | 8.011 | |
| Debt To Assets Ratio | 0.422 | 0.453 | 0.402 | 0.399 | 0.393 | |
| Debt To Equity Ratio | 1.098 | 1.382 | 1.094 | 1.188 | 1.267 | |
| Debt To Capital Ratio | 0.523 | 0.580 | 0.523 | 0.543 | 0.559 | |
| Long Term Debt To Capital Ratio | 0.494 | 0.563 | 0.504 | 0.519 | 0.544 | |
| Financial Leverage Ratio | 2.600 | 3.052 | 2.721 | 2.974 | 3.225 | |
| Working Capital Turnover Ratio | 4.299 | 4.803 | 6.771 | 8.569 | 7.036 | |
| Operating Cash Flow Ratio | 0.848 | 0.902 | 0.710 | 0.807 | 0.981 | |
| Operating Cash Flow Sales Ratio | 0.340 | 0.377 | 0.295 | 0.333 | 0.417 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | 0.952 | 0.927 | 0.920 | 0.949 | |
| Debt Service Coverage Ratio | 3.209 | 1.513 | 3.373 | 2.370 | 3.676 | |
| Interest Coverage Ratio | 11.427 | 1.701 | 8.056 | 7.840 | 9.908 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | 5.966 | 4.453 | 3.991 | 7.509 | |
| Operating Cash Flow Coverage Ratio | 0.402 | 0.405 | 0.320 | 0.360 | 0.426 | |
| Capital Expenditure Coverage Ratio | 17.796 | 20.704 | 13.685 | 12.462 | 19.661 | |
| Dividend Paid And Capex Coverage Ratio | 2.194 | 2.438 | 1.822 | 2.045 | 2.721 | |
| Dividend Payout Ratio | 0.470 | 8.162 | 0.672 | 0.808 | 0.579 | |
| Enterprise Value Multiple | 12.523 | 29.749 | 11.433 | 14.410 | 9.935 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.8% | ▲0.6% | ▲1.2% |
| Ebit Margin | 36.8% | ▲30.9% | ▲10.7% |
| Ebitda Margin | 46.1% | ▲30.7% | ▲11.3% |
| Operating Profit Margin | 39.7% | ▲34.0% | ▲12.4% |
| Pretax Profit Margin | 33.3% | ▲30.9% | ▲10.8% |
| Continuous Operations Profit Margin | 28.9% | ▲27.2% | ▲10.8% |
| Net Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Bottom Line Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Current Ratio | 1.553 | ▼-0.044 | ▲0.126 |
| Quick Ratio | 1.403 | ▼-0.052 | ▲0.121 |
| Solvency Ratio | 0.310 | ▲0.228 | ▲0.122 |
| Cash Ratio | 0.640 | ▼-0.192 | ▲0.050 |
| Price To Earnings Ratio | 17.944 | ▼-225.135 | ▼-45.448 |
| Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Forward Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Price To Earnings Diluted Ratio | 18.103 | ▼-224.976 | ▼-45.396 |
| Price To Earnings Diluted Growth Ratio | 0.011 | ▲2.666 | ▲0.567 |
| Price To Book Ratio | 6.726 | ▲0.767 | ▲1.423 |
| Price To Sales Ratio | 5.186 | ▲1.180 | ▲1.144 |
| Price To Free Cash Flow Ratio | 16.147 | ▲4.970 | ▲3.687 |
| Price To Operating Cash Flow Ratio | 15.240 | ▲4.602 | ▲3.561 |
| Debt To Assets Ratio | 0.422 | ▼-0.030 | ▲0.009 |
| Debt To Equity Ratio | 1.098 | ▼-0.283 | ▼-0.107 |
| Debt To Capital Ratio | 0.523 | ▼-0.057 | ▼-0.022 |
| Long Term Debt To Capital Ratio | 0.494 | ▼-0.069 | ▼-0.031 |
| Financial Leverage Ratio | 2.600 | ▼-0.452 | ▼-0.315 |
| Working Capital Turnover Ratio | 4.299 | ▼-0.504 | ▼-1.997 |
| Operating Cash Flow Ratio | 0.848 | ▼-0.054 | ▼-0.001 |
| Operating Cash Flow Sales Ratio | 0.340 | ▼-0.036 | ▼-0.012 |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | ▼-0.008 | ▲0.005 |
| Debt Service Coverage Ratio | 3.209 | ▲1.696 | ▲0.381 |
| Interest Coverage Ratio | 11.427 | ▲9.726 | ▲3.640 |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | ▼-2.397 | ▼-1.528 |
| Operating Cash Flow Coverage Ratio | 0.402 | ▼-0.004 | ▲0.019 |
| Capital Expenditure Coverage Ratio | 17.796 | ▼-2.908 | ▲0.934 |
| Dividend Paid And Capex Coverage Ratio | 2.194 | ▼-0.244 | ▼-0.050 |
| Dividend Payout Ratio | 0.470 | ▼-7.692 | ▼-1.668 |
| Enterprise Value Multiple | 12.523 | ▼-17.226 | ▼-3.087 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $152.69B | $115.19B | $101.10B | $107.74B | $91.20B | |
| Enterprise value | $170.06B | $131.91B | $120.00B | $127.56B | $112.56B | |
| EV / Sales | 5.78x | 4.59x | 4.43x | 4.68x | 4.12x | |
| EV / Op. cash flow | 16.97x | 12.18x | 14.99x | 14.06x | 9.89x | |
| EV / Free cash flow | 17.98x | 12.80x | 16.17x | 15.29x | 10.42x | |
| EV / EBITDA | 12.52x | 29.75x | 11.43x | 14.41x | 9.94x | |
| Net debt / EBITDA | 1.28x | 3.77x | 1.80x | 2.24x | 1.89x | |
| Current ratio | 1.55x | 1.60x | 1.43x | 1.28x | 1.27x | |
| Income quality | 1.18x | 22.56x | 1.41x | 1.98x | 1.84x | |
| Graham number | $53 | $12 | $43 | $37 | $43 | |
| Graham net-net | -$18 | -$19 | -$22 | -$25 | -$29 | |
| Tax burden | 86.9% | 69.6% | 82.6% | 79.0% | 75.2% | |
| Interest burden | 90.5% | 41.4% | 87.9% | 86.1% | 89.2% | |
| Working capital | $6.53B | $7.17B | $4.80B | $3.21B | $3.16B | |
| Invested capital | $37.43B | $40.84B | $44.89B | $45.89B | $50.07B | |
| Return on assets | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% | |
| Operating ROA | 19.8% | 2.7% | 12.1% | 11.2% | 14.5% | |
| Return on tangible assets | 25.2% | 1.6% | 20.7% | 17.7% | 23.8% | |
| Return on equity | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | |
| Return on invested capital | 20.3% | 2.4% | 11.8% | 10.6% | 12.8% | |
| Return on capital employed | 24.8% | 3.5% | 15.0% | 14.1% | 17.6% | |
| Earnings yield | 5.6% | 0.4% | 5.6% | 4.3% | 6.8% | |
| Free cash flow yield | 6.2% | 8.9% | 7.3% | 7.7% | 11.8% | |
| Capex / Op. cash flow | 5.6% | 4.8% | 7.3% | 8.0% | 5.1% | |
| Capex / Depreciation | 20.4% | 18.9% | 21.7% | 34.6% | 28.2% | |
| Capex / Sales | 1.9% | 1.8% | 2.2% | 2.7% | 2.1% | |
| SG&A / Sales | 19.4% | 21.2% | 22.5% | 20.8% | 19.2% | |
| R&D / Sales | 19.7% | 20.5% | 21.1% | 18.2% | 16.9% | |
| Stock comp / Sales | 3.0% | 2.9% | 2.8% | 2.4% | 2.3% | |
| Intangibles / Total assets | 42.9% | 47.9% | 56.0% | 58.9% | 61.5% | |
| Days sales outstanding | 61d | 56d | 63d | 64d | 60d | |
| Days payables outstanding | 42d | 49d | 31d | 58d | 39d | |
| Operating cycle | 165d | 156d | 163d | 161d | 150d | |
| Cash conversion cycle | 123d | 107d | 132d | 103d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years